BioPharma Services Inc.

biopharmaservices.com

BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in Phase I/IIa as well as Bioequivalence clinical trials with research facilities in Toronto, Canada and Columbia, Missouri.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

XERIS BIOPHARMA ANNOUNCES RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HORIZON THERAPEUTICS PLC FOR XERIJECT™ FORMULATION OF TEPROTUMUMAB

Xeris | November 24, 2022

news image

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc. Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect™, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of tepr...

Read More

Pharmacy Market

NANOTEMPER TECHNOLOGIES UNVEILS BIOTINYLATED TARGET LABELING KIT, EMPOWERING SCIENTISTS IN PHARMA INDUSTRY TO TACKLE CHALLENGING DRUG TARGETS

Businesswire | June 30, 2023

news image

NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal me...

Read More

GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

FierceBiotech | February 03, 2020

news image

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Read More

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

news image

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More
news image

Pharma Tech

XERIS BIOPHARMA ANNOUNCES RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HORIZON THERAPEUTICS PLC FOR XERIJECT™ FORMULATION OF TEPROTUMUMAB

Xeris | November 24, 2022

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc. Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect™, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of tepr...

Read More
news image

Pharmacy Market

NANOTEMPER TECHNOLOGIES UNVEILS BIOTINYLATED TARGET LABELING KIT, EMPOWERING SCIENTISTS IN PHARMA INDUSTRY TO TACKLE CHALLENGING DRUG TARGETS

Businesswire | June 30, 2023

NanoTemper Technologies, creator of biophysical tools for drug discovery, today, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry. This new kit combined with NanoTemper’s exclusive Spectral Shift technology is the preferred orthogonal me...

Read More
news image

GILEAD CLIMBS AS CORONAVIRUS DRUG SHOWS EFFICACY, STARTS TRIAL

FierceBiotech | February 03, 2020

Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. Remdesivir was one of a clutch of drugs tested against Ebola, but it failed to match the efficacy of its rivals, leading...

Read More
news image

CHINA TURNS ROCHE ARTHRITIS DRUG ACTEMRA AGAINST COVID-19 IN NEW TREATMENT GUIDELINES

FiercePharma | March 04, 2020

Some patients infected with the novel coronavirus can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. After seeing promising results in clinical practice, Chinese authorities now recommend a Roche arthritis drug to tackle that rampage. Roche’s blockbuster Actemra, first approved by the U.S. FDA in 2010 for rheumatoid arthritis, can now be used to treat serious coronavirus patients with lung damage, China’s National Health Commissio...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us